Pneumococcal conjugate second or third-dose vaccines (PCVc) in Africa (WHO region)
Africa (WHO region): Pneumococcal conjugate second or third-dose vaccines (PCVc) was 73.0% in 2025. ◆ Volatile
Pneumococcal conjugate second or third-dose vaccines (PCVc) in Africa (WHO region), 2008–2025
Source: World Health Organization, Global Health Observatory.
Analysis
The most recent figure for pneumococcal conjugate second or third-dose vaccines (pcvc) in Africa (WHO region) is 73.0%, measured in 2025.
That represents a change of up 2.8% on the previous year and up 21.7% over ten years.
Over the whole period, pneumococcal conjugate second or third-dose vaccines (pcvc) in Africa (WHO region) peaked at 74.0% in 2019 and was at its lowest, 0.0%, in 2008.
The series is highly variable year to year, so single readings are best treated with caution.
Pneumococcal conjugate second or third-dose vaccines (PCVc) in Africa (WHO region), year by year
| Year | Value | Change |
|---|---|---|
| 2008 | 0.0% | — |
| 2009 | 0.0% | — |
| 2010 | 3.0% | — |
| 2011 | 11.0% | +266.7% |
| 2012 | 22.0% | +100.0% |
| 2013 | 34.0% | +54.5% |
| 2014 | 47.0% | +38.2% |
| 2015 | 60.0% | +27.7% |
| 2016 | 67.0% | +11.7% |
| 2017 | 70.0% | +4.5% |
| 2018 | 73.0% | +4.3% |
| 2019 | 74.0% | +1.4% |
| 2020 | 71.0% | -4.1% |
| 2021 | 66.0% | -7.0% |
| 2022 | 68.0% | +3.0% |
| 2023 | 71.0% | +4.4% |
| 2024 | 71.0% | +0.0% |
| 2025 | 73.0% | +2.8% |
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 0.0% | 0.0% | 0.0% | 2 |
| 2010s | 46.1% | 3.0% | 74.0% | 10 |
| 2020s | 70.0% | 66.0% | 73.0% | 6 |
More health data for Africa (WHO region)
- Measles - number of reported cases 179,400 (2025)
- Total tetanus - number of reported cases 20,578 (2025)
- Diphtheria - number of reported cases 20,261 (2025)
- Pertussis - number of reported cases 12,202 (2025)
- Neonatal tetanus - number of reported cases 1,654 (2025)
- Underweight among adults, BMI < 18.5 kg/m2 (age-standardized estimate) 11.3% (2024)
- Obesity among children and adolescents, BMI-for-age > +2 standard 4.7% (2024)
- Obesity among adults, BMI ≥ 30 kg/m2 (crude estimate) 11.3% (2024)
- Overweight among children and adolescents, BMI-for-age > +1 standard 12.3% (2024)
- Neonatal mortality rate 26.27 (2024)
Frequently asked questions
- What is pneumococcal conjugate second or third-dose vaccines (pcvc) in Africa (WHO region)?
- Pneumococcal conjugate second or third-dose vaccines (pcvc) in Africa (WHO region) was 73.0% in 2025, according to World Health Organization, Global Health Observatory.
- What is the highest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in Africa (WHO region)?
- The highest recorded value was 74.0% in 2019.
- What is the lowest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in Africa (WHO region)?
- The lowest recorded value was 0.0% in 2008.
- How does Africa (WHO region) rank for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Africa (WHO region) ranks 6th out of 11 groups with data for 2025.
- Is pneumococcal conjugate second or third-dose vaccines (pcvc) rising or falling in Africa (WHO region)?
- Over the last ten years it is up 21.7%. The long-run trend across the full record is volatile.
- Where does this Africa (WHO region) data come from?
- The figures come from World Health Organization, Global Health Observatory, published as part of Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 18 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).